IMPACT OF VITAMIN- D SUPPLEMENTATION IN PCOS AND NON-PCOS PATIENTS
Main Article Content
Keywords
polycystic ovarian syndrome, vitamin-d, BMI
Abstract
polycystic ovarian syndrome (PCOS) is the most common endocrine disorder affecting women in reproductive age group. Vitamin D is thought to influence the development of PCOS through gene transcription. A level of 20ng/ml to 50ng/ml is considered adequate for healthy people. Several studies have reported low level of vitamin D in women with PCOS, with average 25- hydroxyvitamin (25-OHD) levels between 11 and 31ng/ml with majority having values less than 20ng/ml (67 to 85%).
Aims- - impact of vitamin- D supplementation in PCOS and non PCOS patients.
Methods and materials- An observational, cross-section, analytical study, conducted in the department of Gynecology and Obstetrics, OPD, Birsa Munda GMC Shahdol for 24 months (1st January 2022 to 1st January 2023) in 60 cases and 30 control. The patients satisfying the inclusion criteria were enrolled in the study following informed written consent. History of the enrolled patients was taken in details with special emphasis on menstrual history, history of excessive weight gain, excessive hair growth and acne.
Results- PCOS patients ranged from the ages 18-39 years with a mean (±sd) ae of 27.13±5.59 years. Menstrual irregularities were more common in PCOS women with a mean menstrual cycle per year 5.63±0.78. FBS and Insulin resistance were common in PCOS group with a mean value of 89.03±14.70 gm/dl and 18.15±8.82 IU/ml, respectively. Acne and hirsutism were significantly higher in PCOS women. BMI was more in PCOS group as compared to the Non PCOS group. Mean BMI in PCOS group was 26.89±4.19 kg/m2. WHR was also found to be more in PCOS women. Mean ratio was 0.91±0.11. The prevalence of Vitamin D deficiency among PCOS women attending the hospital was found to be 11.4%. The risk of deficiency or insufficiency of Vitamin D was 4.75 times more among the patients with PCOS as compared to the patients without PCOS. Vitamin D deficiency was more prevalent among obese women. 57.1% of obese women were deficient in Vitamin D levels. Vitamin D was more prevalent among patients with WHR >0.81.
Conclusion- PCOS patients are more likely to develop low vitamin D levels as compared to those without it. As obese PCOS patients are at a greater risk of Vitamin D deficiency and its later morbidity, they should be followed up more frequently. Obese PCOS women should be advised about weight reduction by lifestyle changes and dietary modification with the inclusion of high protein calcium and vitamin D rich diet and exclusion of fried and oily food items.
A reasonable regime of exercise should be advised to all PCOS patients especially those with more than normal BMI, in order to increase insulin sensitivity. Vitamin D supplements may be considered in treatment of PCOS women having altered vitamin D levels. Insulin sensitizer may be considered in patients with insulin resistance.
References
2. Dunaif, A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews, 18, 774–800.
3. Bethea SW, Nestler JE. Comorbidities in Polycystic ovary Syndrome: their relationship to insulin resistance. Panminerva Med. 2008Dec;50(4):295-304.
4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078-302.
5. Tasali E, Van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clinic. 2008 March;3(1):37-46.
6. March, W.A., Moore, V.M., Willson, K.J. et al. (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction, 25, 544–551.
7. Guzick DS. Polycystic ovary syndrome. Obstet Gynecol.2004; 103(1):181-193.
8. Talbott, E.O., Zborowskii, J.V. & Boudraux, M.Y. (2004) Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence Minerva Ginecologica, 56, 27–39.
9. 4. Alexander, C.J., Tangchitnob, E.P. & Lepor, N.E. (2009) Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Reviews in Obstetrics and Gynecology, 2, 232–239.
10. Holte, J., Bergh, T., Berne, C. et al. (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. Journal of ClinicalEndocrinology and Metabolism, 80, 2586–2593.
11. Barber, T.M., McCarthy, M.I., Wass, J.A.H. et al. (2006) Obesity and polycystic ovary syndrome. Clinical Endocrinology, 5, 137–145.
12. Pasquali, R., Gambineri, A. & Pagotto, U. (2006) The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG: An International Journal of Obstetrics and Gynaecology, 113, 1148.
13. Teede H, Deeks A, Moran L. polycystic syndrome: a complex condition with psychological, reproductive and metabolic manifestation that impacts the health across lifespan.BMC Med. 2010 Jun30;8:41
14. Rotterdam ESHRE/ASRM- Sponsored PCOS Consensus Workshop group. Revised 2003 consensuson diagnostic criteria and long term health risk related to polycystic ovary syndrome (PCOS). Human Reproduction.2004;19(1):41-47.
15. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of poycystic ovary syndrome. Eur J Endocrinol.2002Dec; 147(6):717-25.
16. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine.2006 Aug;30(1):19-26.
17. Shannon M, Wang Y. Polycystic ovary syndrome: a common but often unrecognized condition. J Midwifery Womens Health.2012 May- Jun;57(3):221-30
18. Panidis, D., Balaris, C., Farmakiotis, D. et al. (2005) Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clinical Chemistry, 51, 1691–1697.
19. Hahn, S., Haselhorst, U., Tan, S. et al. (2006) Low serum 25- hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology and Diabetes, 114, 577–583.
20. Yildizhan, R., Kurdoglu, M., Adali, E. et al. (2009) Serum 25- hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 280, 559–563.
21. Wehr, E., Pilz, S., Schweighofer, N. et al. (2009) Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. European Journal of Endocrinology, 0, EJE-9–EJE0432.
22. Pal, L., Shu, J., Zeitlian, G. et al. (2008) Vitamin D insufficiency in reproductive years may be contributory to ovulatory infertility and PCOS. Fertility and Sterility, 90, S14.
23. Holick, M.F. (2007) Vitamin D Deficiency. New England Journal of Medicine, 357, 266–281.
24. Li, HWR, Brereton RE, Anderson RA et al (2001) Vitamin deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 60,1475–1481.
25. Wehr, E., Trummer, O., Giuliani, A. et al. (2011) Vitamin Dassociated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. European Journal of Endocrinology, 164, 741–749.
26. Mahmoudi, T., Gourabi, H., Ashrafi, M. et al. (2010) Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertility and Sterility, 93, 1208–1214.
27. Thys-Jacobs, S., Donovan, D., Papadopoulos, A. et al. (1999) Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids, 64, 430–435.
28. Selimoglu, H., Duran, C., Kiyici, S. et al. (2010) The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 33, 234–238.
29. Kotsa, K., Yavropoulou, M.P., Anastasiou, O. et al. (2009) Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertility and Sterility, 92, 1053–1058.
30. Wehr, E., Pieber, T.R. & Obermayer-Pietsch, B. (2011) Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in PCOS women-a pilot study. Journal of EndocrinologicalInvestigation, 34, 757– 763.
31. Muscogiuri, G., Policola, C., Prioletta, A. et al. (2012) Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clinical Nutrition, PMID:22260937. [Epub ahead of print].
32. National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults ( Adult treatment Panel). Third Report of The National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults ( Adult treatment Panel III) Final Report, Circulation.2002;106:2143-3421.
33. Bethea SW, Nestler JE. Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance. Panminerva Medica.2008;50(4):295-304
34. Azziz R, Wood KS, Reyna R, Key TJ,Knochenhauer ES, Yildiz BO. The prevalence and features of PCOS in an unselected population. The Journal Of Clinical Endocrinology and Metabolism.2004;89(6):2745- 2749
35. Gambineri A, Pelusi C, Vincennati V, Pagotto U and Pasquali R. obesity and the polycystic syndrome. Int J Obes Related Met Dis 2002 July; 26(7):883-96.
36. Majumdar A, Singh TA. Comparision of Clinical Features and healthmanifestation in lean vs. obese Indian women with polycystic ovarian syndrome. Journal of Human Reproductive Sciences. 2009;2(1):12-17
37. Amar Nagesh Kumar1, Jupalle Nagaiah Naidu2, Uppala Satyanarayana3, Medabalmi Anitha4, Krishnan Ramalingam5. ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25–OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME:
38. International Journal of Clinical Biochemistry and Research, January – March 2015;Vol.2(1):22-26
39. Ramanand SJ, Ghongane BB, Ramanand JB, Patwardhan MH, Ghanghas RR, Jain SS. Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocr Metab 2013; 17: 138-45.
40. Fruzatti F, Perini D, Lazzarini V. Adolescent girls with polycystic ovary syndrome showing different phenotype have a different metabolic profile associated with increasing androgen levels. Fertil. Steril. 2008;92(2):626- 634.
41. Diamanti Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and type of dislipidemia in PCOS. Trends Endocrinol. Metab. 2007;18:280-285.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Richa Sharma
SR OBGY, Gajra Raja Medical College, Gwalior.
Dr Rini Bachotiya
Assistant Professor, RD Gardi Medical College, Ujjain.